Navigation Links
Clinical trial seeks to improve patient treatment for Crohn’s disease
Date:1/4/2010

Robarts Clinical Trials at The University of Western Ontario in London, Canada, has been awarded a 4.7 million dollar grant to conduct a randomized controlled trial evaluating treatment options for Crohn's disease. The outcome is expected to lead to a more streamlined treatment path and better disease management for patients. Abbott, the global health care company, has provided a grant to complete research for the REACT (Randomized Evaluation of an Algorithm for Crohn's Treatment) study.

Crohn's disease is a chronic inflammatory disorder that is characterized by symptoms of diarrhea, abdominal pain and gastrointestinal bleeding. It typically effects younger people and can result in serious complications such as bowel obstruction. Although conventional anti-inflammatory treatments such as prednisone improve symptoms, they are associated with important side effects and are only partially effective. Many patients require surgery to treat the disease.

The REACT study will be carried out at 40 gastroenterology practices in Canada and Belgium. The sites will be randomly assigned to treat patients with Crohn's disease to either a conventional management strategy featuring gradual escalation of drug therapy or a newer paradigm that features early use of combined immunosuppression with a tumor necrosis factor alpha blocking drug and an anti-metabolite.

"This trial builds on the results of recent studies that suggest use of combined therapy early in the course of treatment yields superior long-term results," says Dr. Brian Feagan, the lead investigator for the study. "We are excited about this project since it is the first large-scale, community-based evaluation of this approach. We expect that patients treated with combination therapy will be more likely to enter remission and rates of hospitalization and health-care utilization will be reduced." Dr. Feagan is the Director of Robarts Clinical Trials and a professor in the Department of Medicine at Western's Schulich School of Medicine & Dentistry.


'/>"/>

Contact: Kathy Wallis
kwallis3@uwo.ca
519-661-2111 x81136
University of Western Ontario
Source:Eurekalert

Related medicine news :

1. Michael J. Fox Foundation Awards $2 Million for Clinical Research on Postural Instability and Gait Disturbances in Parkinsons Disease
2. Crohn's & Colitis Foundation Presents National Science Awards to Clinical and Scientific Thought-Leaders in Inflammatory Bowel Diseases
3. Skyscape Offers Medical Professionals Real Time Clinical Decision Application on Google Android
4. Clinical trial advances new approach to re-sensitizing breast cancer
5. HealthWyse Clinical and Financial Point of Care Software Addresses OASIS-C Regulations and More
6. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
7. Most Antidepressants Miss Key Target of Clinical Depression
8. Quantros(TM) Unveils Clinical Cafe, Social Networking Website for Healthcare Professionals Focused on Safety, Quality and Compliance
9. Pharmacyclics, Inc. Reports Interim Safety and Clinical Data from a Phase I/II Clinical Trial of its Oral HDAC Inhibitor PCI-24781 in Lymphoma at the American Society of Hematology Annual Meeting
10. Reportlinker Adds Emerging Clinical Trial Locations - India: Market Dynamics and the Changing Healthcare and Regulatory Environment
11. UM Clinical Research Building awarded prestigious LEED Building Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Ushio ... These lamps offer an instant energy-saving solution for F32T8 fluorescent lamps on most ... disconnect ballasts. These 50,000 hour rated lamps utilize the existing electronic ballast, saving ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... ... ... Overseer at The House of Yahweh in Abilene, Texas, has published a new post that ... Yisrayl says with so many titles and names for the Creator, it’s hard for many ... Scripture, backed with a lot of research, the truth is undeniable. , “If you ...
(Date:4/28/2017)... ... ... Intellitec Solutions announced the publication of a case study ... solution that integrates to their PointClickCare EHR software package. With the guidance of ... now has the capability to achieve its goal for a comprehensive EHR solution, ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  CVS Pharmacy, the retail division of CVS ... design to enhance the retail customer experience with ... and expanded beauty selections paired with informational signage ... offerings. Together with its innovative digital programs, these ... experience at CVS Pharmacy.  "Pharmacy ...
(Date:4/20/2017)... Research and Markets has announced the ... Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies ... ... was valued at US$ 7,167.6 Mn in 2015, and is ... a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/20/2017)... 2017 Research and Markets has announced ... Services Market Analysis By Service (Manufacturing, Research), By Country, (Brazil, ... 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing services ... Low drug registration cost in Latin American countries ...
Breaking Medicine Technology: